POPULARITY
Categories
103 episodes with annual meetings
111 episodes with annual meetings
87 episodes with annual meetings
85 episodes with annual meetings
54 episodes with annual meetings
66 episodes with annual meetings
56 episodes with annual meetings
53 episodes with annual meetings
49 episodes with annual meetings
38 episodes with annual meetings
39 episodes with annual meetings
25 episodes with annual meetings
29 episodes with annual meetings
56 episodes with annual meetings
29 episodes with annual meetings
19 episodes with annual meetings
23 episodes with annual meetings
26 episodes with annual meetings
23 episodes with annual meetings
37 episodes with annual meetings
25 episodes with annual meetings
30 episodes with annual meetings
19 episodes with annual meetings
14 episodes with annual meetings
17 episodes with annual meetings
13 episodes with annual meetings
16 episodes with annual meetings
16 episodes with annual meetings
15 episodes with annual meetings
15 episodes with annual meetings
13 episodes with annual meetings
14 episodes with annual meetings
16 episodes with annual meetings
11 episodes with annual meetings
10 episodes with annual meetings
11 episodes with annual meetings
19 episodes with annual meetings
15 episodes with annual meetings
11 episodes with annual meetings
13 episodes with annual meetings
8 episodes with annual meetings
9 episodes with annual meetings
17 episodes with annual meetings
10 episodes with annual meetings
9 episodes with annual meetings
14 episodes with annual meetings
9 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
9 episodes with annual meetings
10 episodes with annual meetings
9 episodes with annual meetings
8 episodes with annual meetings
14 episodes with annual meetings
12 episodes with annual meetings
7 episodes with annual meetings
9 episodes with annual meetings
10 episodes with annual meetings
7 episodes with annual meetings
4 episodes with annual meetings
11 episodes with annual meetings
14 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
7 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
8 episodes with annual meetings
9 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
9 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
9 episodes with annual meetings
13 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
12 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
3 episodes with annual meetings
5 episodes with annual meetings
6 episodes with annual meetings
14 episodes with annual meetings
5 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
7 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
10 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
3 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
20 episodes with annual meetings
3 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
12 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
7 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
3 episodes with annual meetings
7 episodes with annual meetings
2 episodes with annual meetings
6 episodes with annual meetings
2 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
10 episodes with annual meetings
3 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
9 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
12 episodes with annual meetings
3 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
10 episodes with annual meetings
2 episodes with annual meetings
4 episodes with annual meetings
60 episodes with annual meetings
3 episodes with annual meetings
Abdul and Katelyn discuss the latest news in public health, which includes: Trump's $100,000 H1-B visa fee, which is could significantly hurt staffing in rural hospitals A new 100% tariff on certain imported brand-name drugs RFK Jr's announcement that the FDA is re-evaluating the abortion medication mifepristone A new scientific breakthrough that's giving hope to people with Huntington's Disease Then Abdul sits down with Dr. Aziz Rahman, an American physician who recently completed a medical mission in Gaza. Dr. Rahman offers a gripping account of the devastation in Gaza, and the heroic efforts of doctors serving there. Check out our shop at store.americadissected.com for our new America Dissected merch – including logo shirts, hoodies and mugs. And don't miss our “Vaccines Work. Science Matters.” t-shirts! This show would not be possible without the generous support of our sponsors. America Dissected invites you to check them out. This episode was brought to you by: Boll & Branch: For a limited time get 20% off your first set of sheets plus free shipping at BollAndBranch.com/AD. Quince: Go to Quince.com/AD for free shipping on your order and 365-day returns. APHA: Listeners of this podcast get a 10% discount for the 2025 Annual Meeting and Expo using code: Dissected25.
Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos, Dr Hans Lee, and Dr Noopur Raje, moderated by Dr Joseph Mikhael, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Raje (3:17) Integrating Bispecific Antibodies into the Management of R/R MM — Dr Lee (20:38) Potential Role of Antibody-Drug Conjugates and Cereblon E3 Ligase Modulators in Therapy for MM — Prof Dimopoulos (40:37) CE information and select publications
In this episode of the American Shoulder and Elbow Surgeons Podcast, hosts Dr. Brian Waterman and Peter Chalmers are at the SECEC Annual Meeting in Rotterdam. Author: Dr. Maxime Antoni Guest Host: Dr. Robert Gillespie Title: Functional impact and risk factors for humeral implant migration in stemless RSA Author: Dr. Bjorn Salomonsson Guest Host: Dr. Brad Schoch Title: Survival analysis of total shoulder arthroplasty for glenohumeral osteoarthritis. Comparison of anatomical and reversed implants a registry study Author: Dr. Arno Macken Title: Combining pre-operative benzoyl peroxide and subcutaneous iodine after incision is effective in reducing cutibacterium acnes presence in shoulder surgery; results of the C3PO trial. Author: Dr. Samuel Antuna Topic: Shoulder Arthroplasty: first clinical results of robotic-assisted shoulder replacements
David Wynn and Renee Merker, and Joe Jackson give listeners a peek into what to expect from the upcoming Annual Meeting in San Antonio, Texas!For More Information Visit pmpa.org/podcasts
This week on Taking The Pulse, Heather and Seth record at the NCLifeSci 2025 Annual Meeting with Bobby Patrick, Senior Vice President of Government Affairs at AdvaMed. Bobby shares how the world's largest medical technology association is advocating for expanded Medicare coverage of breakthrough devices, navigating the evolving role of AI in diagnostics, and addressing supply chain and tariff challenges. We also explore how AI is enhancing physician decision-making and how patient trust and data security remain central to innovation. Tune in now for a timely look at the policy and technology shaping the future of medtech.
R. Ross Burris, Shareholder, Polsinelli, and Lindsey L. Lonergan, Senior Associate General Counsel, Wellspan Health, discuss current trends and developments related to audits and proactive strategies for dealing with audits. They cover issues related to CMS claim review programs, the increase in commercial audits versus government payer audits, artificial intelligence, Unified Program Integrity Contractor audits, and the 60-day rule. Ross and Lindsey spoke about this topic at AHLA's 2025 Annual Meeting in San Diego, CA.Watch this episode: https://www.youtube.com/watch?v=iorXAhX0o9ELearn more about the AHLA 2025 Annual Meeting that took place in San Diego, CA: https://www.americanhealthlaw.org/annualmeeting Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.
From the aloha spirit of Waikiki Beach to the heartfelt connections in Denver, my recent travels reminded me of a powerful truth: we can only give what we've received. In this new episode of the Inside Out Leadership Podcast, I share behind-the-scenes stories from two unforgettable keynote experiences—one with a leading financial advisory firm in Hawaii and the other at the NASP 2025 Annual Meeting & Expo. Join me as I unpack the lessons, the people, and the moments that continue to shape how I live and lead from the inside out.
Chuck and Chris are joined by the co-chairs of the ASSH Annual Meeting, Lindley Wall and Carl Harper. They share insights on ALL of the exciting plans for the robust annual meeting in Vancouver. Join us and get excited about the. meeting with a few insider tips.We mention a new book about Sterling Bunnell. If you are not going to the meeting and would like to purchase a copy, use this link.https://american-society-for-surgery-of-the-hand.myshopify.com/products/dr-sterling-bunnell-from-son-of-the-gold-rush-to-founding-father-of-hand-surgeryWe are in need of a podcast intern! We would appreciate any referrals!See www.practicelink.com/theupperhand for more information from our partner on job search and career opportunities.The Upper Hand Podcast is sponsored by Checkpoint Surgical, a provider of innovative solutions for peripheral serve surgery. To learn more, visit https://checkpointsurgical.com/.As always, thanks to @iampetermartin for the amazing introduction and concluding music.For additional links, the catalog. Please see https://www.ortho.wustl.edu/content/Podcast-Listings/8280/The-Upper-Hand-Podcast.aspx
Trajectories of Fidgety Movements in Infants with and without medical complexity.This paper is a finalist for AACPDM's highest honour - the Gayle G Arnold award, chosen and highlighted by the scientific review committee for it's high quality.We look ahead at The American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) Conference - the 79th Annual Meeting!“Celebrating Resilience” October 15-18, 2025, to be held in New Orleans, LA.
The September 26 edition of the AgNet News Hour closed out the week with one of the state's most important agricultural voices. Hosts Nick Papagni and Josh McGill welcomed Shannon Douglas, president of the California Farm Bureau, for a wide-ranging conversation on water, regulation, trade, and the survival of California's family farms. Douglas, a former FFA member and now a proud “FFA mom,” shared her passion for youth in agriculture. She reminded listeners that FFA isn't just for farm kids — it can spark careers in science, technology, and leadership for students from all backgrounds. “We have tremendous career opportunities in agriculture,” she said, pointing to data showing over four jobs per crop science graduate in California. On policy, Douglas highlighted three critical issues she and her team took to Washington, D.C.: Labor and Immigration – Farmers can't function without a reliable, respected workforce. Trade – California's high-quality specialty crops depend on international markets. The Farm Bill – Current versions overlook specialty crops and need to better support healthy food programs. She also raised alarm over Proposition 50, which she called a “surprise challenge” for farmers. By reshaping district maps in a gerrymandered way, rural representation could be severely weakened. One proposal would lump Modoc County in with Sausalito, a pairing Douglas called absurd. She stressed that rural voices must be preserved in California's political process. Perhaps the most staggering statistic Douglas shared: in the last 15 years, California farmers have seen regulatory costs increase by nearly 1,400%. That crushing burden has contributed to a 20% loss of family farms in just the past decade. “These are small farms, family farms — and we don't want to see this loss continue,” she warned. Despite the challenges, Douglas struck an optimistic tone. She pointed to innovation, automation, and the grit of California's multi-generation farmers as reasons for hope. She also encouraged more farmers to get involved in Farm Bureau, which represents 26,000 members across 54 counties, and to attend the Annual Meeting in December with its theme: Strong Roots, Bright Future. For Papagni and McGill, Douglas' leadership was clear: she's the right person to carry California's farmer stories into the halls of power. Listen to the full conversation with Shannon Douglas on the AgNet News Hour by clicking below, or on your favorite podcast a
London has once again been recognized as the world's leading city brand, topping the Brand Finance Global City Index for the second consecutive year. But what does it mean for a city to be a “brand,” and what factors contribute to London's enduring global appeal?In this episode of Brand & New, we explore how London has built and sustained its reputation as a destination admired worldwide for all the right reasons: its dynamic business environment, its rich cultural heritage, its academic and scientific excellence, and its ability to innovate and adapt. And as INTA gets set to head to London for its 2026 Annual Meeting, we ask what lessons other cities and global businesses can learn from London's example.We are joined by two distinguished voices, Konrad Jagodzinski, Place Branding Director at Brand Finance, and Tracy Halliwell MBE, Director of Tourism, Conventions, and Major Events at London & Partners. Together, they discuss how London continues to thrive as a global brand and why its blend of commerce, culture, and creativity keeps it at the top of the world stage.This episode of Brand & New is hosted by Willard Knox.Related Resources:About Konrad JagodzinskiAbout Tracy HalliwellAbout Brand FinanceBrand Finance lobal City Index 2024 About INTA 2026 Annual Meeting
Abdul begins the show with a major announcement about America Dissected. Then, he and Katelyn discuss: RFK Jr's Autism report, which points to an unproven link between autism and acetaminophen Last week's ACIP meeting, where RFK Jr's new appointees approved new recommendations on the Covid booster and MMRV vaccines The end of the Covid summer wave, and how it compared to last year Then Abdul sits down with Dr. Demetre Daskalakis, who recently resigned in protest from the FDA. They discuss the chaos at the agency and the future of public health under RFK Jr. Check out our shop at store.americadissected.com for our new America Dissected merch – including logo shirts, hoodies and mugs. And don't miss our “Vaccines Matter. Science Works.” t-shirts! This show would not be possible without the generous support of our sponsors. America Dissected invites you to check them out. This episode was brought to you by: OneSkin: Get 15% off OneSkin with the code DISSECTED at https://www.oneskin.co/ #oneskinpod Incogni: Take your personal data back with Incogni! Use code DISSECTED at the link below and get 60% off an annual plan: https://incogni.com/dissected APHA: Listeners of this podcast get a 10% discount for the 2025 Annual Meeting and Expo using code: Dissected25.
Send us a textJoin host Dr. Stephanie Ihnow for a conversation with the new SRS President, Dr. Suken Shah. They discuss his vision for the year ahead, the guiding motto shaping his presidency, and exciting details about the next Annual Meeting in Sydney, Australia. *The Scoliosis Research Society (SRS) podcast is aimed at delivering the most current and trusted information to clinicians that care for patients with scoliosis and other spinal conditions. From news in the world of spinal conditions, to discussions with thought leaders in the field, we aim to provide up-to-date, quality information that will impact the daily practice of spinal conditions.
Physical health providers, health systems, and hospitals often struggle with how to handle behavioral health issues as they arise. Anna Whites, Attorney, Anna Whites Law Office, and Matthew W. Wolfe, Shareholder, Baker Donelson Bearman Caldwell & Berkowitz PC, discuss strategies for integrating physical and mental health care. They share their respective journeys into behavioral health law, how providers can add behavioral health care to their practices, legal and compliance challenges, and the future of integrated care. Anna and Matthew spoke about this topic at AHLA's 2025 Annual Meeting in San Diego, CA.Watch this episode: https://www.youtube.com/watch?v=wcDbdn6mD-4Learn more about the AHLA 2025 Annual Meeting that took place in San Diego, CA: https://www.americanhealthlaw.org/annualmeeting Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.
The American Neurological Association's 150th Annual Meeting held in Baltimore last week was a milestone meeting celebrating 150 years of progress, discovery, advances in science, and the remarkable work of academic neurologists and neuroscientists over the past century and a half. The meeting—ANA2025—featured outstanding plenary sessions, professional development workshops, interactive lunch workshops, special interest groups, cross-cutting special interest groups, the celebrated poster hall, satellite symposia, and several opportunities to network and connect with colleagues and friends. Dr. Michelle Johansen of Johns Hopkins University School of Medicine, immediate past chair of the ANA Education Innovation Committee, engaged with meeting attendees to learn more about their experience at ANA2025 and what they think about the ANA. Listen in as meeting attendees share their insights, meeting highlights, and enthusiasm for the ANA during Dr. Johansen's boots on the ground interactions with them. From the Presidential Symposium to the closing sessions, learn about ANA2025, the science and research shared, and the reactions of those who were in Baltimore to experience it.
Welcome to Ozempic Weightloss Unlocked, the podcast where the science and the stories around Ozempic are put into focus for anyone curious about medical breakthroughs, health, and real-world results. Today we dive into the latest findings shaking up the world of weight management with Ozempic, a brand name for semaglutide. New research published mid-September in The Lancet Diabetes & Endocrinology shows that a triple-sized weekly dose of Ozempic—specifically 7.2 milligrams—helped people with obesity lose even more weight than the currently approved lower dose. Adults who took this higher dose lost on average nearly 19 percent of their body weight. Nearly half of participants on this regimen lost at least 20 percent, and a third lost a quarter or more. Similar benefits were seen for those with type 2 diabetes, with the higher dose leading to a 13 percent weight loss, compared to 10 percent for the lower dose.But there is more than just the numbers on the scale. Participants on the higher dose saw improvements in waist circumference, blood pressure, blood sugar, and cholesterol numbers. Importantly, the higher dose was found to be both safe and generally well tolerated. The most frequent issues were digestive, like nausea and diarrhea, but these tended to resolve over time with no increased risk of severe low blood sugar or other serious events. Researchers from the Wharton Medical Clinic in Canada concluded that even greater health improvements could be reached in the future, but they called for more research into the long-term effects and safety as use expands.Adding to the buzz, a recent study out of Denmark raises important questions about how long people actually stick with Ozempic for weight management. According to research presented at the Annual Meeting of The European Association for the Study of Diabetes, more than half of adults who began using the drug for weight loss ended up quitting within one year. Factors behind this drop-off included cost, side effects, and potential health complications. When treatment is stopped, most people regain weight, highlighting that Ozempic is not a short-term fix and needs to be taken long term for sustainable results. The findings raise red flags since discontinuing the medication can undermine hard-won health improvements, and the high price also risks making access unequal.Ozempic is not just for the scale—it has heart-protective effects too. Novo Nordisk, the pharmaceutical company behind the drug, released results from the REACH trial showing that once-weekly Ozempic reduced the risk of heart attack, stroke, or hospitalization for heart failure by a significant 25 percent compared to an older medication called dulaglutide. That is a substantial bonus, especially for those with both obesity and cardiovascular risk factors.Researchers are also learning that how you eat can affect how well Ozempic works. A team from Kyoto University found that people who eat in response to sights and smells of food are more likely to see weight loss benefits from Ozempic, compared to those who eat mainly for emotional reasons. Those with emotional eating patterns might require additional behavioral or psychological support for the medication to be most effective.The science is clear—GLP-1 receptor agonists like Ozempic can be life-changing, delivering substantial and safe weight loss, along with significant improvements for blood sugar, heart health, and metabolic risk factors. But to sustain progress, long-term commitment is key, and the therapy works best alongside changes in eating habits and ongoing support.Thank you for tuning in to Ozempic Weightloss Unlocked. If you found today's update helpful, be sure to subscribe for more news and expert insights on this quickly evolving topic. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI
This month, Public and Member Relations Coordinator Amanda Busby tells us all about Annual Meeting and capital credits, coming your way soon.
Dr. Teekz Yenpasook has overcame lymphoma, founded health clinics and mentored underrepresented students in dermatology and medicine. If you are interested in his story, please check out his previous podcast with DIGA where he dives deeper into his journey into dermatology. Now a dermatology resident at the University of Minnesota, Dr. Teekz shares insights on skin of color dermatology, LGBTQ+ health, and building more inclusive dermatologic education. In this episode, we discuss why representation matters in dermatology and his advice for medical students interested in skin of color research, mentorship, and advocacy. We hope you enjoy! Please explore the links below for amazing SOC resources that Dr. Teekz provided.How to get involved with Skin of Color Dermatology:Mentorship Programs & Diversity InitiativesAAD Diversity Mentorship Program: A funded, one-month mentorship for underrepresented in medicine (URiM) students to gain hands-on experience with a dermatologist mentor. https://www.aad.org/member/career/awards/diversitySkin of Color Society (SOCS) Mentorship Program: Connects students with experts in skin of color dermatology for long-term guidance and offers observership grants. https://skinofcolorsociety.org/resources/student-resourcesNth Dimensions Summer Internship (NDSI): An eight-week clinical and research internship for first-year medical students interested in competitive specialties like dermatology. https://www.nthdimensions.org/programsAAD "Pathways: Inclusivity in Dermatology" Initiative: A major program focused on increasing the number of Black, Latino, and Indigenous dermatologists through scholarships, workshops, and mentorship. https://www.aad.org/member/career/diversity/pathwaysProfessional Societies & Interest GroupsSkin of Color Society (SOCS): The leading professional organization dedicated to advancing health equity in the care of patients with skin of color. https://skinofcolorsociety.org/American Academy of Dermatology (AAD): The largest professional society for dermatologists in the United States. https://www.aad.org/Dermatology Interest Group Association (DIGA): The national organization for medical student dermatology interest groups, offering resources on research, mentorship, and away rotations. https://derminterest.com/Skin of Color Community: An organization focused on building an inclusive community and cultivating self-advocacy in healthcare through events and partnerships. https://www.skinofcolorcommunity.org/Educational Resources & ConferencesAAD Skin of Color Curriculum: A free, comprehensive online curriculum with dozens of modules to train physicians on diagnosing and treating conditions in patients with skin of color. https://learning.aad.org/Listing/Skin-of-Color-Curriculum-5719AAD Basic Dermatology Curriculum: A foundational resource for medical students to review dermatological terms and treatments for common disorders. https://www.aad.org/member/education/residents/bdcAAD Upcoming Events & Meetings: A calendar of national AAD meetings, including the Annual Meeting and Innovation Academy, which are key networking and learning opportunities. https://www.aad.org/member/meetings-education/upcoming-eventsAAD Free Skin Cancer Screening Program (SPOTme®): Information on how to volunteer for or host a free community skin cancer screening. https://www.aad.org/member/career/volunteer/spot---DIGA Instagram: @derminterestToday's Host, Katelyn: @katsteng---For questions, comments, or future episode suggestions, please reach out to us via email at derminterestpod@gmail.com---Music: "District Four" Kevin MacLeod (incompetech.com) Licensed under Creative Commons:By Attribution 4.0 License: http://creativecommons.org/licenses/
On Sept. 6, 2025, Southwestern Electric Cooperative held its 87th Annual Meeting of Members at the American Farm Heritage Museum in Greenville. In this month's podcast, hear the addresses from CEO Bobby Williams and Board President Jerry Gaffner in their entirety.
Fertility & Sterility on Air is at the European Society of Human Reproduction and Embryology 41st Annual Meeting in Paris, France (Part 2)! In this episode, our hosts Kate Devine, Eve Feinberg, and Micah Hill cover: Discussing the state of assisted reproductive technology in Brazil with Giuliano Bedoschi (01:01) Whole transcriptome and genome sequencing of standard embryo biopsies can potentially reduce failed euploid transfers with Kaylene Ready and Jeremy Grushcow (09:03) The use of AI in ovarian stimulation with Eduardo Hariton (19:45) Modeling embryonic adhesion at cellular resolution within a microfluidic endometrium-on-a-chip platform with Sofia Zaragozano (32:33) Assessing the ploidy status of atypically fertilised embryos – recovery of embryos for potential clinical use with Sharyn Stock-Myer (40:41) Role of micronutrients and probiotics supplementation on reproductive outcomes in an oocyte donation program with Sara Maggi and Silvia Bonta (42:47) Male infertility, life expectancy, and long-term health risks: exploring what can sperm reveal about health with Omar Ammar (58:00) Mitochondrial DNA ‘reversal' is common in children born following meiotic spindle transfer, potentially reducing the efficacy of mitochondrial replacement therapies with Munuse Savash (01:05:57) View Fertility and Sterility at https://www.fertstert.org/
Kinsella on Liberty Podcast, Episode 474. “Where The Common Law Goes Wrong,” 2025 Annual Meeting, Property and Freedom Society, Bodrum, Turkey (Sep. 19, 2025). This will also be podcast later on the Property and Freedom Podcast. Below are my notes, Shownotes provided by Grok, and the transcript. This recording is from my iphone. Professional recording and video will be uploaded later. See also Sebastian Wang, "Stephan Kinsella on the Common Law: Lessons from Bodrum 2025," Libertarian Alliance [UK] Blog (Sep. 19, 2025). Grok Shownotes Show Notes: Stephan Kinsella's “Where the Common Law Goes Wrong” – Property and Freedom Society 2025 Annual Meeting Introduction and Context Stephan Kinsella delivered his talk, “Where the Common Law Goes Wrong,” at the Property and Freedom Society's 2025 Annual Meeting in Bodrum, Turkey, on September 21, 2025. Introduced by Hans-Hermann Hoppe, who shared a brief anecdote about media bias in translating Donald Trump's interactions, Kinsella's presentation revisits themes from his earlier PFS talks in 2012 and 2021, focusing on the interplay between libertarian principles, Roman law, and the common law. Drawing on his recent work, including the Universal Principles of Liberty (co-authored with Alessandro Fusillo, David Dürr, FreeMax, and Patrick Tinsley, under Hoppe's guidance), Kinsella emphasizes the organic development of law and critiques the modern tendency to equate law with legislation. He humorously recounts preparing for the talk with his trainer, who mistook “common law” for “common law marriage,” highlighting the need to clarify legal concepts for a broader audience. Defining Law and Its Evolution Kinsella begins by distinguishing types of law: descriptive (e.g., laws of physics, economics) and normative (e.g., moral codes, legal systems). Legal laws, he argues, blend normative guidance with descriptive consequences, aiming to achieve justice through property rights. He contrasts the modern view of law as statutory decrees—illustrated by tax protesters demanding to “show me the law”—with its historical roots in decentralized systems like Roman law (500 BC–565 AD) and English common law (1066–present). These systems evolved organically through court decisions, with Roman law preserved in Justinian's Corpus Juris Civilis and later rediscovered in Bologna around 1070, influencing European civil codes. Kinsella notes that post-1789 democratic shifts and bureaucratic growth led to an explosion of legislation, overshadowing these private law traditions. Roman Law vs. Common Law The talk explores why Anglo-American scholars, like Hayek and Leoni, often praise the common law's spontaneous order while overlooking Roman law's similar decentralized origins. Kinsella cites Hoppe's observation, from Democracy: The God That Failed, that the common law's non-codified nature may serve lawyers' interests by making it less accessible to laypeople, unlike Europe's clearer civil codes. He refutes the misconception that civil law systems inherently embody totalitarian principles (“all that is not permitted is forbidden”), attributing Europe's socialism to separate legislation, not civil codes. Both Roman and common law, Kinsella argues, offer valuable insights for libertarians, despite the former's neglect in free-market scholarship. Libertarian Law and Rationalism Critique Kinsella critiques the rationalistic tendency among libertarians to design top-down “libertarian law codes,” as exemplified by Rothbard's hope for a comprehensive code in The Ethics of Liberty. Such approaches, he argues, ignore context and the limits of deductive reasoning, echoing Hayek's critique of constructivist rationalism. Law, as a practical response to scarcity and conflict, developed through real-world judicial decisions over centuries. Kinsella suggests that libertarian law should evolve organically, using Roman and common law as starting points, guided by principles like non-aggression but subject to scrutiny f...
At ALEC's 52nd Annual Meeting in Indianapolis, Kentucky Sen. Steve Rawlings didn't just arrive as a first-time Policy Champion, he arrived as a fighter. An attorney by training and a lawmaker by conviction, Rawlings has been pushing back against unchecked bureaucratic power and laying the groundwork for reforms that protect liberty and strengthen state sovereignty. Special Guest: Steve Rawlings.
The employment law landscape is evolving rapidly, especially for health care employers. Timothy A. Hilton, Partner, Husch Blackwell LLP, and Gary McLaughlin, Partner, Mitchell Silberberg & Knupp LLP, discuss the areas of greatest concern for health care employers. They cover wage and hour issues, considerations related to remote work, and religious and ADA accommodation issues. Timothy and Gary spoke about this topic at AHLA's 2025 Annual Meeting in San Diego, CA.Watch this episode: https://www.youtube.com/watch?v=T_ltW2fsTWoLearn more about the AHLA 2025 Annual Meeting that took place in San Diego, CA: https://www.americanhealthlaw.org/annualmeeting Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.
At the Society of Hematologic Oncology 2025 Annual Meeting, CancerNetwork® spoke with a variety of experts about notable clinical developments and trial results across the hematologic oncology landscape. Throughout the meeting, clinicians and researchers discussed the latest data and initiatives in myelofibrosis, multiple myeloma, lymphoma, and other types of blood cancer. Francesca Palandri, MD, PhD, an adjunct professor in the Department of Medical and Surgical Sciences at the University of Bologna in Bologna, Italy, shared insights from a session focused on exploring predictive markers for the efficacy of ruxolitinib (Jakafi) among patients with myelofibrosis.1 Noting variance in response rates as well as possibilities of disease progression or treatment discontinuation associated with ruxolitinib, Palandri emphasized the importance of assessing predictors of response to better orient clinical decision-making strategies regarding the agent's use. She also highlighted how factors such as cytopenic phenotype, higher peripheral blast counts, and higher burden of disease may impact response rates and survival among patients. Additionally, Sundar Jagannath, MD, a professor of Medicine specializing in hematology and medical oncology at the Icahn School of Medicine at Mount Sinai and The Tisch Cancer Institute, spoke about his presentation on potentially defining a cure in the management of multiple myeloma.2 He described the importance of “chang[ing] the dialogue” in multiple myeloma to give hope to patients and encourage physicians to engage in patient care more optimally. By defining a cure in multiple myeloma, Jagannath stated, it may be possible to offer more finite durations of treatment and stop therapy with the confidence that patients will not relapse. Finally, Adam J. Olszewski, MD, an associate professor of medicine at The Warren Alpert Medical School of Brown University, discussed his work on the phase 3 SUNMO trial (NCT05171647).3 Findings from this presentation showed that mosunetuzumab-axgb (Lunsumio) plus polatuzumab vedotin-piiq (Polivy; M-Pola) reduced the risk of progression or death by 59% vs rituximab (Rituxan) with gemcitabine and oxaliplatin (R-GemOx) in relapsed/refractory large B-cell lymphoma (LBCL). Olszewski also outlined next steps for refining treatment strategies in this patient population. References Palandri F. Predictive markers for ruxolitinib in MF. Presented at the Society of Hematologic Oncology 2025 Annual Meeting; September 3-6, 2025; Houston, TX. Jagannath S. Is it time to say “CURE” in multiple myeloma? Presented at the Society of Hematologic Oncology 2025 Annual Meeting; September 3-6, 2025; Houston, TX. Westin J, Zhang H, Kim W, et al. Mosunetuzumab plus polatuzumab vedotin is superior R-GemOx in transplant-ineligible patients with R/R LBCL: primary results of the phase III SUNMO trial. Presented at the Society of Hematologic Oncology 2025 Annual Meeting; September 3-6, 2025; Houston, TX. Abstract ABCL-1492.
Fertility & Sterility on Air is at the European Society of Human Reproduction and Embryology 41st Annual Meeting in Paris, France (Part 1)! In this episode, our hosts Kate Devine, Eve Feinberg, and Micah Hill cover: outcomes from programmed ovulatory frozen embryo transfer cycles vs. modified natural frozen embryo transfer cycles with Philippos Edimiris (0:56), non-invasive preimplantation genetic testing using metabolomics with Sofia Nunes (9:23), optimizing timing of modified natural cycle frozen embryo transfer cycles with Amelie Johansen and Kristine Løssl (17:46), mechanisms and consequences of ovarian aging with Francesca Duncan (27:18), comparing pregnancy loss rates in natural cycle vs. artificial cycle endometrial preparation prior to euploid embryo transfer with Caroline Roelens (38:24), and endometrial health and reproductive outcomes with Shari Mackens(49:44). View Fertility and Sterility at https://www.fertstert.org/
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.” He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.” In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support. https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections. The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs. Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs. In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide). The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems. Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study. “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries. They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment. https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year. The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app. https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care. Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations. The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe. The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market. The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems. Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation. Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options. It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems. “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra. Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes. The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations. ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna. The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape. “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.” https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results… Well maybe that's overplaying it a little. Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better. Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/ XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic. Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana. “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp. He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could. “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp. He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s. “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp. Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes. Bob credits his late wife, Donna, for helping him beat the odds. “She has been key in that I always ate on time.” They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner. “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp. Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps. “I'm not satisfied with the sensors they have today. I just don't think they're accurate.” To many, Bob's survival is extraordinary. To him, it's luck. “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp. And through it all, optimism has been his compass. “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp. He still welds nearly every day. Not because he has to, but because it keeps him going. “As long as I keep doing something like this, I will not be in the nursing home,” said Delp. https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond. Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?: An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.
Abdul and Katelyn discuss the week in public health, which includes: RFK Jr's MAHA Report, and why it fails to deliver meaningful change The leaked report that revealed RFK Jr will tie Tylenol use to autism The firing of CDC Director Susan Monarez, and the mass resignations that followed RFK Jr's Senate testimony, which included a grilling from top Republicans Then Abdul talks to Natalie Foster, president of the Economic Security Project, about the power of guaranteed income in health outcomes. Check out our shop at store.americadissected.com for our new America Dissected merch – including logo shirts, hoodies and mugs. And don't miss our “Vaccines Work. Science Matters.” t-shirts! This show would not be possible without the generous support of our sponsors. America Dissected invites you to check them out. This episode was brought to you by: Quince: Go to Quince.com/AD for free shipping on your order and 365-day returns. APHA: Listeners of this podcast get a 10% discount for the 2025 Annual Meeting and Expo using code: Dissected25. Incogni: Take your personal data back with Incogni! Use code DISSECTED at the link below and get 60% off an annual plan: https://incogni.com/dissected
Tonight's show comes to you from the 2025 NWA Annual Meeting in Huntsville at the Von Braun Civic Center. Janice Bunting is the Executive Director of the NWA stops by first to talk to the panel. She's pulled off an amazing event this year under trying circumstances. Throughout the evening, other notable leaders in the weather industry will also stop by to chat with our panel about this year's meeting — sharing their insights, highlights, and what it all means for the future of meteorology. Our email officer Jen is continuing to handle the incoming messages from our listeners. Reach us here: email@weatherbrains.com. Bob Baron and other sponsors of the Annual Meeting (04:20) Roadmap for the NWA going forward (07:30) Louis Uccellini talks about the initial NWA in the early days of the organization (27:00) Force multiplier nature of social media (45:00) Panel discussion with industry's leading digital meteorologists (59:00) Hand-drawn animations for the conference (01:06:00) Goals for the upcoming year in NWA (01:10:00) Cooperation with AMS (01:14:00) Nate Johnson discusses student support within the organization (01:26:00) Nate's IWT (Integrated Warning Team) takeaways (01:30:30) Dr. Chuck Graves stops by to chat with the panel (01:48:00) The Astronomy Outlook with Tony Rice (01:54:55) This Week in Tornado History With Jen (01:57:05) E-Mail Segment (No segment this week - STAY TUNED!) and more! Web Sites from Episode 1025: Alabama Weather Network Picks of the Week: James Aydelott - James Aydelott photographed in back of patrol car Jen Narramore - Foghorn Rick Smith - Out Troy Kimmel - Foghorn Kim Klockow-McClain - Foghorn John Gordon - A New Spin On Waterspout Forecasting (Published August 2014) John Gordon - A Waterspout Forecasting Technique Bill Murray - Foghorn James Spann - FCC Proposes Modernization of the Nation's Alerting Systems The WeatherBrains crew includes your host, James Spann, plus other notable geeks like Troy Kimmel, Bill Murray, Rick Smith, James Aydelott, Jen Narramore, John Gordon, and Dr. Kim Klockow-McClain. They bring together a wealth of weather knowledge and experience for another fascinating podcast about weather.
Since we are at the very start of the holiday season, at least for businesses (and yes it is the start of the holiday season for business), company leaders both big and small have to start planning. Whether it's holiday parties, sales kickoffs, or, of course, annual meetings, the planning has to begin now, and it's worth planning them the right way. In the case of annual meetings, the importance is apparent. Most companies only get all the employees together once a year, and typically that is at the annual meeting, so every piece of information and every learning activity that is done is vital with little room for filler. Despite this, annual meetings can be prime suspects for employee disengagement. Forcing a group of team members to learn and discuss necessary parts of business right after most have had a break and are just starting to get back into the swing of things is naturally going to lead to tuning out. It doesn't have to be that way though. Stick around for five excellent tips to ensure every employee at the annual get together is focused and learning every step of the way. Show Notes: 5 Tips to Solve Team Disengagement in Annual Meetings(https://www.leadersinstitute.com/5-tips-to-solving-team-disengagement-with-team-building-activities/)
Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.” Our full disclosures are available in the transcript of this episode. And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%. And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting. So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course. And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media: @ASCO on X (formerly Twitter) ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera
New Zealand First wants to make KiwiSaver compulsory, and increase contributions to eight, then 10 percent. Political reporter Russell Palmer has more.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Kenneth Waller, Chief Executive Officer of Norwalk Community Health Center. He shares how the organization is scaling services, leveraging data and AI, and staying mission-focused while navigating funding challenges and industry uncertainty.
Tonight's Guest WeatherBrain is a meteorologist, climatologist, instructor, and now author. She has a brand new book just released titled "Wilder Weather: What Laura Ingalls Wilder Teaches Us About Weather, Climate, And Protecting What We Cherish". In her book, she digs deep into Wilder's depictions of weather events and helps readers connect past weather to present weather. She's worked at NOAA for over 23 years. Dr. Barbara Boustead, it's great to have you on the show! Our email officer Jen is continuing to handle the incoming messages from our listeners. Reach us here: email@weatherbrains.com. Introduction to Laura Ingalls Wilder and he r background (13:00) Entire Little House on the Prairie series (14:45) Analyzing 1880s weather records in Dakota Territory (19:00) Laurapalooza Conference (21:45) Weather in Wilder's other works (24:15) Further examples of Wilder's writings about weather events (34:30) Today's different climate from the era of authors like Charles Dickens (44:00) Climate is the past, present, and future (50:00) Encouraging teachers to use "Wilder Weather" in lesson plans (58:30) Weather folklore (01:00:00) Where can you order "Wilder Weather"? (01:10:00) Tips for aspiring authors (01:24:00) The Astronomy Outlook with Tony Rice (01:11:20) This Week in Tornado History With Jen (01:12:50) E-Mail Segment (01:14:05) and more! Web Sites from Episode 1024: Alabama Weather Network Wilder Weather "Wilder Weather: What Laura Ingalls Wilder Teaches Us About the Weather, Climate, and Protecting What We Cherish" by Dr. Barbara Boustead Picks of the Week: Dr. Barbara Boustead - "The Beautiful Snow" by Cindy Wilson James Aydelott - Meteogram for Camargo, OK/90+mph winds Jen Narramore - Merry violent phenomenon in Morbihan on 2 September Rick Smith - Here's one of the first photos of a tornado ever Troy Kimmel - Out Kim Klockow-McClain - NWA 50th Annual Meeting in Huntsville, AL John Gordon - ATR-72 nearly flipped over from 99 mph winds in Corsica John Gordon - Reagan's near-death experience in 1983 Bill Murray - "The Weather Gods Curse the Gettysburg Campaign" by Jon M. Nese and Jeffrey Harding James Spann - Sandblasted to Death: 1935 Labor Day Hurricane The WeatherBrains crew includes your host, James Spann, plus other notable geeks like Troy Kimmel, Bill Murray, Rick Smith, James Aydelott, Jen Narramore, John Gordon, and Dr. Kim Klockow-McClain. They bring together a wealth of weather knowledge and experience for another fascinating podcast about weather.
Illinois Rep. John Cabello explains how Republicans in a super minority can still fight back, rally citizens & hold the majority accountable. Special Guest: John Cabello.
Show Highlights: Field to Market's unique positioning in the ag value chain. [04:51] Why equal voices matter in a cross-sector coalition. [06:26] What are Field to Market's core functions and tools? [07:57] The value of real ag sector experience for coalition leadership. [10:42] Sustainability insights by agribusinesses from Field to Market's Annual Meeting. [15:00] M&A lessons from harnessing diversity in coalitions. [27:41] The role of collaborative data in the Triscuits supply chain. [31:24] How U.S. Cotton Trust Protocol assesses sustainability. [36:26] Discover what's next for Field to Market—and participate. [40:45] To learn more about Field to Market, go to https://fieldtomarket.org/. To check out Field to Market's membership, visit https://fieldtomarket.org/our-members/ To learn how Field to Market defines sustainability, visit https://fieldtomarket.org/defining-sustainability/ To join the Sustainable Agriculture Summit, visit https://fieldtomarket.org/contact-us/events/sustag-summit/. Find Carrie on LinkedIn at https://www.linkedin.com/in/carrievollmersanders/. If you are interested in connecting with Joe, go to LinkedIn: https://www.linkedin.com/in/joemosher/, or schedule a call at www.moshercg.com.
"THANK YOU," from the entire team at Biblical Higher Ed Talk. A special message from Phillip Dearborn.A sneak peek into Season 5Speakers for ABHE 79th ANNUAL MEETING: A Time to Lead -- February 11-13, 2026. We are approaching 10,000 downloadsBiblical Higher Ed Talk is to be a part of The Higher Ed Marketer Podcast Network. To hear this interview and many more like it, subscribe on Apple Podcasts, Spotify, or our website, or search for Biblical Higher Ed Talk in your favorite podcast player.Hosted by Ausha. See ausha.co/privacy-policy for more information.
Join host David Werho (UC San Diego/Rady Children's) and guests Carly Scahill (Colorado Children's), Lillian Su (Phoenix Children's), and Yaeji Kim (IG: @chd_doodles) as they discuss the upcoming 2025 PCICS Annual Meeting in Austin, TX, co-hosted by The Texas Center for Pediatric and Congenital Heart Disease at Dell Children's Hospital. We speak about many of the plenary sessions, breakouts, social events, and things to do in Austin! Host/Editor/Producer: David Werho Platinum Sponsor: Prolacta BioScience
WeatherBrains Episode 1023A is a preview of the upcoming 2025 NWA Annual Meeting in Huntsville, AL. The meeting is only two weeks away from the date of recording (August 25th, 2025). Show veteran Kevin Laws joins us to dive into the upcoming NWA Annual Meeting in Huntsville. He currently serves as the SOO (Science and Operations Officer) of the Birmingham, AL NWS office. Kevin, it's great to see you again. David from the Texas Storm Chasers also drops in to chat with the panel about what to expect at the meeting. Our email officer Jen is continuing to handle the incoming messages from our listeners. Reach us here: email@weatherbrains.com. Tropics remain quiet (02:45) Starting the dialogue of a changing business model (07:55) Baby steps toward progress in the field starting over 15 years ago (11:00) Gatekeeping and resentment among various sectors in meteorology (12:00) Objectives of the upcoming Annual Meeting (23:00) The outdated concept of TV market boundaries (36:00) NWA registration procedures (44:00) How do we define expertise in 2025? (48:30) What will the broadcast transition look like moving forward? (50:45) The Astronomy Outlook with Tony Rice (No segment for this episode) This Week in Tornado History With Jen (No segment for this episode) E-Mail Segment (No segment for this episode) and more! Web Sites from Episode 1023A: 2025 NWA Annual Meeting September 6-10th, 2025 Huntsville AL Alabama Weather Network Alabama Weather Network on Facebook Picks of the Week: James Aydelott - Cool noon temperatures in Oklahoma Jen Narramore - Out Rick Smith - The OCS/Mesonet Ticker Troy Kimmel - Foghorn Kim Klockow-McClain - Foghorn John Gordon - Out Bill Murray - Out James Spann - Foghorn The WeatherBrains crew includes your host, James Spann, plus other notable geeks like Troy Kimmel, Bill Murray, Rick Smith, James Aydelott, Jen Narramore, John Gordon, and Dr. Kim Klockow-McClain. They bring together a wealth of weather knowledge and experience for another fascinating podcast about weather.
Our preview of the upcoming AACPDM Conference in New Orleans USA.We look ahead at The American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) Conference - the 79th Annual Meeting!“Celebrating Resilience” October 15-18, 2025, to be held in New Orleans, LA. We catch up with AACPDM First Vice President Dr Theresa Sukal-Moulton and Scientific Program Committee Co-Chair Dr Paige Church.You can still register at the link below!https://www.aacpdm.org/events/2025
A Conversation in Veterinary Pathology - The A.C.V.P. Podcast
In this episode, we chat with Dr. Olivia Patania and Dr. Lauren Stranahan of the ACVP Student Engagement Committee. They discuss veterinary student happenings at the 2024 ACVP/ASVCP annual meeting and upcoming exciting events for the 2025 Annual Meeting in New Orleans, LA. Have you thought about volunteering for ACVP? We hear how they started and why it's important. The Doctors also discuss the best time in your career to get interested in veterinary pathology - spoiler alert - it's anytime! So grab a comfy chair and get ready for a conversation with Dr. Olivia Patania and Dr. Lauren Stanahan. ___ Links Veterinary Student Engagement - https://acvp.org/training/veterinary-student-engagement/ 2025 ACVP Pathletes Registration 2025 Annual Meeting in NOLA Student Externship Scholarships Season 02, Episode 04 - A Conversation with Dr. Mara Varvil Season 02, Episode 05 - A Conversation with Dr. Keith Nelson of the Student Externship Scholarship Committee ACVP Errors in Publications Portal ACVP Training Program Accreditation ___ ACVP Student Engagement's Social Media Facebook: ACVP Veterinary Student Engagement Instagram: acvp_student_engagement ____ ACVP Social Media Facebook - ACVP Meetings and Topics Instagram - americancollegevetpath X (Twitter) - @ACVP LinkedIn - AMERICAN COLLEGE OF VETERINARY PATHOLOGISTS ____ Acronyms STP = Society of Toxicologic Pathology DTF = Davis Thompson Foundation ____ Music: Guestlist by Podington Bear, licensed under an Attribution-NonCommercial 3.0 International License. The contents of this audio do not necessarily reflect the opinions of the American College of Veterinary Pathologists (ACVP) or the participants' affiliations. Spoken audio content and associated photos are the property of the American College of Veterinary Pathologists, 2025.
One of North Carolina's newest legislators tackles property tax reform with confidence and conviction. North Carolina Representative Brian Echevarria spoke with ALEC Director of Policy Advancement and Media Relations Lars Dalseide on ALEC TV about turning a family challenge into a political calling by championing property tax reform. Special Guest: Brian Echevarria.
ALEC Board Member Jim Dotson shares how Arkansas climbed into the top 10 in economic competitiveness and why it won't stop there. Special Guest: Jim Dotson.
We're jumping into your feed midweek to share an interview with Adam from this past June by our friends at the Radio Davos podcast. We'll be back with a new episode on Friday. Radio Davos is a weekly podcast from the World Economic Forum that looks at the biggest challenges facing the world, and how they might be tackled. Find it wherever you get podcasts or at wef.ch/podcasts. Video-podcasts are posted at https://www.youtube.com/@wef/podcasts. This episode of Radio Davos, an interview with Adam Tooze, was recorded at the World Economic Forum's Annual Meeting of the New Champions in Tianjin, China on June 25, 2025. Historian and podcaster Adam Tooze says we are at a turning point in history - as the Trump administration upends decades of assumptions on geopolitics, trade and the economy. Coinciding with the dawn of artificial intelligence, the rise of China, and demographic shifts are adding to transformative changes for us all. CNBC anchor Chery Kang joins us in the studio at AMNC25 to co-host the episode. This is a video-podcast, watch it on our YouTube channel: http://wef.ch/3GFeAvl Related podcasts: Halfway through 2025, reasons to be optimistic in a turbulent year Three experts on how to understand the USA Tariffs, globalization, and democracy, with Harvard economist Dani Rodrik Check out all World Economic Forum podcasts on wef.ch/podcasts: YouTube: https://www.youtube.com/@wef Radio Davos - subscribe: https://pod.link/1504682164 Meet the Leader - subscribe: https://pod.link/1534915560 Agenda Dialogues - subscribe: https://pod.link/1574956552 Social handles: LinkedIn https://www.linkedin.com/in/robin-pomeroy/ https://www.linkedin.com/company/world-economic-forum/ https://www.linkedin.com/company/cnbc/ https://www.linkedin.com/in/chery-kang-ab5430175/https://www.linkedin.com/showcase/cnbc-international/ X @RobinPomeroyEd @adam_tooze @wef @cherykang@cnbci @OnesandToozePod @ForeignPolicy Learn more about your ad choices. Visit megaphone.fm/adchoices
On this episode of Soundbites of the Annual Meeting, we talked to Kimberly Haugstad, CEO of RareRising and a longtime rare disease advocate who is also the parent of a child with severe hemophilia. In her conversation with ASGCT's Communications Committee Chair, Lynnea Olivarez, Kimberly discusses: why patients, as the "lived experience experts" are so important to rare disease communications advice for scientists who would like to engage more directly with patient communities what's giving her hope right now Listen and subscribe to the ASGCT Podcast Network so you don't miss any episodes!Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.
In this special episode of the IPhO Podcast, Waleed Elsweesy, Current National Student Officer for Marketing & Partnerships, sits down with Melissa Rodenbach, IPhO Vice President, Marketing and Communications; and Daniel Ghattas, Former National Student Officer for Marketing & Partnerships and current first-year Fellow at Pfizer in U.S. & Global Medical Affairs, Hematology/Oncology; to talk all things IPhO Annual Meeting! They answer some of the most common student questions: Why should I attend as a P1, P2, or P3? What makes the meeting valuable for P4s preparing for fellowship recruitment? How can I make the most of networking and content sessions? What deadlines do I need to know about now? Whether you're just starting your journey exploring the industry or you're preparing to take your biggest step yet, this episode gives you insider advice on how to navigate the meeting, connect with industry leaders, and leave with a plan for success.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Peter Banko, President and Chief Executive Officer, Baystate Health. Peter shares insights on improving organizational agility through streamlined decision-making, addressing access challenges with a coordinated care model, and balancing flexible work with community and cultural revitalization.
At the 52nd ALEC Annual Meeting, Michigan Speaker Matt Hall described his priorities as rooted in the belief that economic growth and public safety go hand in hand. By focusing on a business climate that rewards investment, infrastructure spending that delivers results, and policies that respect the rule of law, he believes Michigan can compete with the strongest states in the nation while protecting the communities that call it home. Special Guest: Matt Hall.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Stephanie Everett, Administrator of Mountrail Bethel Home and Chief Executive Officer of Mountrail County Medical Center. She shares her journey from foundation director to CEO, highlights a $53 million expansion project, and discusses the importance of listening to staff, addressing rural staffing challenges, and embracing technology to deliver the best possible patient care.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Dr. Cliff Megerian, Chief Executive Officer, University Hospitals. Dr. Megerian shares how UH is leading with a culture of compassion, advancing patient-centered hospitality, addressing financial pressures with strategic efficiency, and cultivating a resilient workforce through retention and internal career development.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Stephanie Martinez, Executive Director and Associate Chief Nursing Officer for the Care Continuum, Boston Medical Center Health System. She shares how multidisciplinary efforts to reduce length of stay improved care systemwide, and discusses the importance of supporting an evolving nursing workforce through retention strategies and shared decision-making.
© 2020-2025 Ivy Podcast Discovery LLC
